Ozempic Online: Cost, Prescriptions, Telehealth Access, and Candidacy Explained

Can you get Ozempic online?

Yes, through a licensed prescriber and not otherwise. Ozempic appears in FDA's drug listing with a marketing status of Prescription [3], and FDA's guidance on unapproved GLP-1 drugs says patients should obtain a prescription from their doctor and fill it at a state-licensed pharmacy [2].

That same guidance lists telehealth red flags for consumers [2]. A seller that does not require screening and a prescription by a licensed doctor before providing medicine is one. So is a seller with no licensed doctor available to answer questions after the medicine arrives. FDA also lists labels with spelling errors or a pharmacy name that looks fraudulent, and medicine that arrives in broken or damaged packaging or without instructions for use [2].

What a prescriber checks before writing the prescription

The Ozempic label lists two contraindications: a personal or family history of medullary thyroid carcinoma or MEN 2, and a prior serious hypersensitivity reaction to semaglutide or to an excipient [1]. The boxed warning covers the thyroid entry: semaglutide caused thyroid C-cell tumors in rodents at clinically relevant exposures, and whether it does so in humans is unknown [1].

The label's warnings make up the rest of the screen: acute pancreatitis, with the drug to be discontinued if pancreatitis is suspected; acute gallbladder disease; acute kidney injury from volume depletion; diabetic retinopathy complications in patients with type 2 diabetes; hypoglycemia when combined with insulin or a sulfonylurea; severe gastrointestinal reactions, with the drug not recommended in severe gastroparesis; serious hypersensitivity; and pulmonary aspiration during general anesthesia or deep sedation [1].

Two label details that come up often. No dose adjustment is recommended for renal or hepatic impairment [1]. And the label says to discontinue Ozempic in women at least 2 months before a planned pregnancy because of the long washout period [1].

What Ozempic is approved for, and what it is not

Three labeled uses [1]:

• improve glycemic control in adults with type 2 diabetes, as an adjunct to diet and exercise;
• reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease;
• reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

There is no weight-loss indication on the Ozempic label [1]. The semaglutide product approved for weight reduction is Wegovy, which FDA describes as approved for weight reduction in persons with obesity or overweight [5].

On dosing, the label starts at 0.25 mg once weekly for 4 weeks, a dose it does not describe as a maintenance dose, then moves to 0.5 mg; steps to 1 mg and then 2 mg come only after at least 4 weeks at the current dose [1]. For the kidney indication, escalation goes to 1 mg after at least 4 weeks at 0.5 mg [1]. For a missed dose, the label says to give it within 5 days and otherwise skip it [1].

Who is a candidate for Ozempic?

The labeled population is adults with type 2 diabetes [1]. Within that group, those with the most specific label support are people who also have established cardiovascular disease or chronic kidney disease, since those are separate approved uses backed by outcome trials [1][6][7]. Safety and efficacy in pediatric patients have not been established [1].

A personal or family history of medullary thyroid carcinoma or MEN 2, or a prior serious hypersensitivity reaction to semaglutide or an excipient, rules the drug out under the label [1]. Severe gastroparesis is a caution rather than a contraindication: the label says the drug is not recommended in those patients [1].

Compounded semaglutide sold online

FDA says compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing [2]. It also reports dosing errors with compounded injectable semaglutide, including patients measuring the wrong dose, clinicians miscalculating, and doses above the labeled maximum, and states that semaglutide sodium and semaglutide acetate salts are different active ingredients from the approved drug, with no lawful basis for compounding that it is aware of [2]. As of 2026-05-31 FDA had received 990 adverse event reports for compounded semaglutide and says this likely undercounts [2]. FDA also carries a warning about counterfeit Ozempic [2].

What the trials show

SUSTAIN 7 compared semaglutide with dulaglutide head to head in 1,201 adults with type 2 diabetes on metformin over 40 weeks. HbA1c fell 1.5 and 1.8 points on semaglutide 0.5 and 1 mg versus 1.1 and 1.4 points on dulaglutide 0.75 and 1.5 mg, and weight fell 4.6 and 6.5 kg versus 2.3 and 3.0 kg [9].

SUSTAIN FORTE compared 2 mg with 1 mg in 961 adults over 40 weeks: HbA1c fell 2.2 versus 1.9 points and weight 6.9 versus 6.0 kg, while the Ozempic label gives 2.1 versus 1.9 points and HbA1c below 7% in 64% versus 56% of patients [10].

Two outcome trials sit behind the cardiovascular and kidney indications. In SUSTAIN 6 (3,297 adults with type 2 diabetes, 104 weeks), cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 6.6% on semaglutide versus 8.9% on placebo (HR 0.74) [6]. In FLOW (3,533 adults with type 2 diabetes and chronic kidney disease), kidney failure, a 50% or greater eGFR decline, or kidney or cardiovascular death occurred in 18.7% versus 23.2% (HR 0.76) over a median 3.4 years, and the trial was stopped early at an interim analysis [7].